- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 22 May 2025 | 15 May 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Thursday May 22 2025 inter alia: 1) To consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and financial year ended March 31 2025; and 2) To consider and recommend final dividend if any on the equity shares of the Company for the financial year ended March 31 2025. Further as per the provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for designated persons of the Company has been closed from April 1 2025 and shall open after 48 hrs post declaration of financial results of the Company. Recommendation of final dividend of Rs. 4/- per equity share of Rs. 10 each (at the rate of 40%) for FY25. Outcome of Board Meeting of the Company held on May 22, 2025 Appointment of Secretarial Auditor Update on Promoters Reclassification Request (As Per BSE Announcement Dated on 22.05.2025) | ||
| Board Meeting | 19 Mar 2025 | 19 Mar 2025 |
| Proposed de-merger of Identified Business of Arco Lab Private Limited, a wholly owned subsidiary of the Company. | ||
| Board Meeting | 30 Jan 2025 | 24 Jan 2025 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday January 30 2025 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from January 1 2025 and shall open after 48 hrs post declaration of un-audited financial results by the Company. Outcome of Board Meeting - Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024. Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company effective February 1, 2025. Change in designation of Mr. Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective April 5, 2025. Change in Registered office of the Company (As Per BSE Announcement dated on 30.01.2025) | ||
| Board Meeting | 26 Nov 2024 | 26 Nov 2024 |
| Intimation of Record Date under Regulation 42 of SEBI Listing Regulations | ||
| Board Meeting | 24 Oct 2024 | 18 Oct 2024 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday October 24 2024 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from October 1 2024 and shall open after 48 hrs post declaration of financial results by the Company. The above information will also be available on the website of the Company at www.strides.com. This is for your kind information and record purposes. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2024. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half-year ended September 30, 2024 (As Per BSE Announcement Dated on 24.10.2024) | ||
| Board Meeting | 29 Jul 2024 | 22 Jul 2024 |
| Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Announcement of Board meeting under Regulation 29 of SEBI Listing Regulations. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2024. (As Per BSE Announcement dated on 29.07.2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.